Aromatase inhibitors and diabetes risk in breast cancer
Part of Cancer, Hormones & metabolism clinical trials.
This study looks at how aromatase inhibitors, a type of hormone therapy for breast cancer, affect blood sugar and diabetes risk. It compares women taking these drugs to those on tamoxifen or healthy women, to see if there are changes in glucose control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a post-menopausal woman (no period for 12 months or had ovaries removed).
- You have hormone receptor positive breast cancer, DCIS, or a high-risk breast condition.
- You are planning to start, or have started within the last 6 months, an aromatase inhibitor.
- You do not have diabetes and have not taken medications that affect blood sugar recently.
- Your fasting blood sugar is under 126 mg/dL and your HbA1c is under 6.5%.
- You have not had stomach or weight-loss surgery that changes how food moves through your gut.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how aromatase inhibitors (a type of hormone therapy for breast cancer) affect your heart and brain health over time. It compares women with breast cancer who have taken these drugs to healthy women of similar age.
This study looks at how starting a common hormone therapy for breast cancer (aromatase inhibitors) affects your heart and brain health over the short term. It compares women starting this treatment to healthy women who are not on the therapy.
This study tests whether a special anti-inflammatory diet can help reduce side effects in breast cancer survivors who are taking aromatase inhibitors after menopause. You would be randomly assigned to either follow the diet for 6 months or continue your usual diet, and your health will be monitored.
This trial tests whether switching to a different aromatase inhibitor or using standard treatments works better for managing side effects in breast cancer survivors. It aims to help you stay on hormone therapy longer with fewer discomforts.
This study looks at how early hormone therapy affects metabolism in women with ER+ breast cancer. It aims to understand changes in blood sugar, fat, and weight, which could help doctors support your health during treatment.
This study tests if metformin, a common diabetes medicine, can help reduce insulin resistance in women who finished chemotherapy for early-stage breast cancer. It aims to improve long-term health and prevent future problems.
Hear when a new HER2 Positive Breast Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.